biotech / news / / Benzinga
Oral Semaglutide Shows Superior Glycaemic Control.
The PIONEER TEENS trial is the first to evaluate an oral GLP-1 receptor agonist in youth.
KEY POINTS
- Oral semaglutide reduced HbA1c by 0.83% versus placebo at 26 weeks in ages 10–17.
- Novo Nordisk plans to seek label expansion for Rybelsus and Ozempic pill in the U.S. and EU soon.
- Metformin fails to maintain glycaemic control in about half of adolescent patients with type 2 diabetes.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →